1. Home
  2. QS vs ADPT Comparison

QS vs ADPT Comparison

Compare QS & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo QuantumScape Corporation

QS

QuantumScape Corporation

HOLD

Current Price

$5.44

Market Cap

3.6B

ML Signal

HOLD

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$24.42

Market Cap

4.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QS
ADPT
Founded
2010
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
4.1B
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
QS
ADPT
Price
$5.44
$24.42
Analyst Decision
Hold
Strong Buy
Analyst Count
6
9
Target Price
$9.38
$17.78
AVG Volume (30 Days)
16.5M
2.0M
Earning Date
04-22-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
19.15
63.89
EPS
N/A
N/A
Revenue
N/A
$276,976,000.00
Revenue This Year
N/A
$3.98
Revenue Next Year
$1,827.70
$22.72
P/E Ratio
N/A
N/A
Revenue Growth
N/A
54.77
52 Week Low
$4.77
$12.00
52 Week High
$19.07
$26.87

Technical Indicators

Market Signals
Indicator
QS
ADPT
Relative Strength Index (RSI) 40.61 49.26
Support Level $4.77 $23.92
Resistance Level $7.21 $26.16
Average True Range (ATR) 0.26 1.07
MACD -0.02 -0.25
Stochastic Oscillator 3.74 16.81

Price Performance

Historical Comparison
QS
ADPT

About QS QuantumScape Corporation

QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles and other applications. The company's solid-state lithium-metal battery technology is designed to offer greater energy density, faster charging, and enhanced safety. Its battery cells have none of the host materials used in conventional nodes. The company operates in one operating segment only.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: